It is unclear whether hypertension and antihypertensive medication use are associated with breast cancer. In order to examine these associations, we conducted a case-control study among women aged 50-75 years. Breast cancer cases were ascertained via a populationbased cancer registry (n ¼ 523) and controls were ascertained via random-digit-dialing (n ¼ 131). Participants completed a self-administered questionnaire which queried history of hypertension, antihypertensive medication use and risk factors. Unconditional logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals (CI), adjusted for age, body mass index (BMI), diabetes, smoking, alcohol use, menopausal status, family history of breast or ovarian cancer, age at first full-term pregnancy and education.
Introduction
Breast cancer continues to be the leading cause of cancer morbidity and the second leading cause of cancer mortality among women in the US. 1 Rates of obesity and obesity-related conditions such as diabetes and hypertension are on the rise 2 and also contribute to morbidity and mortality. Although there is a growing body of literature on the relation between obesity and post-menopausal breast cancer risk, the pathways responsible are still under investigation. 3 It has been hypothesized that hypertension and breast cancer may be associated owing to shared risk factors such as high body mass index (BMI) or metabolic syndrome, 4 or common pathophysiologic pathways including those involved in insulin resistance, 5 and hormone synthesis and metabolism. 6 Several studies have examined associations between hypertension and cancer risk. Although there appears to be consistent evidence linking hypertension with both renal cancer 7, 8 and endometrial cancer particularly among obese women, 9-11 the results for breast cancer have been less consistent. At least two studies have reported a positive association of hypertension with breast cancer risk, 9 ,12 whereas others have not reported an association with breast cancer risk 4, 13, 14 or mortality. 6 Because the relationship between hypertension and breast cancer risk is still unclear, we wanted to further examine this association. The purpose of this study was to assess the relationship between self-reported history of hypertension and antihypertensive medication use and breast cancer risk in a population-based case-control study. In addition, we wanted to assess whether stratification by BMI and age may influence the relationship between hypertension and breast cancer risk.
Methods

Study population
The population under study includes breast cancer cases diagnosed in Orange County, California, during the 1-year period beginning 1 March 1994. Eligible probands were identified through the existing population-based cancer registry of the Cancer Surveillance Program of Orange County (CSPOC). Description of CSPOC and details of data collection methods have been reported previously. [15] [16] [17] Patients with breast cancer were identified through CSPOC within 6 months of diagnosis.
Consecutive incident cases of breast cancer with diagnosis between 1 March 1994 and 28 February 1995 were eligible for inclusion in the study. For the present analysis, women between the ages of 50-75 years were included. Five hundred and twenty-three cases completed questionnaires with information on history of hypertension. Data from the larger study have been reported previously. 18, 19 Female controls between 50 and 75 years of age (frequency matched to cases by age) who had no personal history of cancer were randomly selected from Orange County residents using random digit dialing between December 1997 and February 1999. The present analyses include 131 female controls who completed questionnaires with information on history of hypertension.
Seven hundred and twelve breast cancer probands completed a telephone interview and 572 (80.3%) of these participants also completed a self-administered epidemiological risk factor questionnaire (RFQ). Probands who completed the RFQ were of similar age as those who did not (mean age 62.0 and 63.7 years, respectively) and also had a similar race distribution (96.0 and 95.0% of white race, respectively). Of the 572 breast cancer probands who returned the RFQ, 523 had completed information about history of hypertension and were included in the present analyses. Cases completing the hypertension-related portion of the RFQ did not differ significantly from those who had missing data for these questions with respect to age (P ¼ 0.23) or race (P ¼ 0.75). Four hundred and fourteen control subjects completed the telephone interview, and of these 142 (34.3%) completed the mailed RFQ. Control subjects who completed the RFQ were similar with respect to age (mean age 61.1 and 60.1 years, respectively) and race (92.5 and 90.1% white, respectively) as subjects who did not complete the RFQ. The present analyses include 131 control women who had available data on history of hypertension and antihypertensive medication use. Controls completing the hypertension-related portion of the RFQ did not differ significantly from those who had missing data for these questions with respect to age (P ¼ 0.07) or race (P ¼ 0.78).
Study measures
Hypertension and hypertensive use. The selfadministered epidemiologic RFQ queried on history of hypertension/high blood pressure and diabetes with the age at diagnosis by category of 'below age 30', '30-49' or '50 or older'. Respondents were also asked to indicate if they had taken certain medications regularly for 1 month or longer (cases were instructed to indicate medications taken 2 or more years before cancer diagnosis) including 'water pills for high blood pressure or other reasons', 'reserpine' and 'other blood pressure medication'. If respondents had ever taken the medication, they were instructed to indicate age first started use and total years of use. In addition, the RFQ elicited information on demographics, reproductive history (age at menarche and parity) and menopausal status, lifetime smoking status, height and weight, personal history of medical conditions, education, alcohol use and ethnicity. Case subjects were asked to complete the questionnaire with information pertaining to the year before diagnosis. Telephone interviews elicited family history information on first-degree relatives of the proband.
The study protocol was approved by the University of California, Irvine Institutional Review Board, and written informed consent was obtained from all study participants (IRB numbers HS91-137 and HS96-496).
Data analysis
Descriptive statistics (frequencies and percentages for categorical variables or means and standard deviations for continuous variables) were calculated for cases and controls. Variables included reference age (continuous), race (white, black, Asian/Pacific Islander, or other/unknown), age at first full-term pregnancy (nulliparous, p25, 425 years), menopausal status (pre/peri-, or post-menopausal), BMI (continuous, weight (kg)/height (m)
2 ), family history of breast or ovarian cancer (none, at least one firstdegree relative with breast or ovarian cancer), education (ocollege graduate, college graduate), smoking history defined as at least 100 cigarettes smoked over lifetime (never, ever), alcohol use in year before reference date (none, any) and history of diabetes (no, yes).
In order to compare cases and controls with respect to history of hypertension and antihypertensive medication use, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate relative risk using unconditional logistic regression. The independent variable 'treated hypertension' was created by combining self-reported information on whether the proband had ever been diagnosed with hypertension with the antihypertensive medication questionnaire items. Those who reported both a diagnosis of hypertension and ever use of antihypertensive medications were included in the 'treated hypertension' category. Each model also included the following covariates as defined above: age, age at first full-term pregnancy, family history of breast or ovarian cancer, diabetes, smoking status, regular alcohol use in year before reference date, BMI, menopausal status and education. Tests for trend were calculated by treating categorical variables as continuous in the logistic models.
In addition, unconditional logistic regression was used to examine risk of breast cancer associated with hypertension stratified by reference age and BMI, including covariates listed above. Reference age (50-64, 65-75 years) and BMI (o25, X25 kg/m 2 ) were dichotomized. All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Distributions of demographic and other variables for cases and controls are presented in Table 1 were more likely to report a positive family history of breast or ovarian cancer than controls (18.3%). Women who reported both having a history of hypertension and taking antihypertensive medications had a statistically significant increased risk of breast cancer than women without a history of treated hypertension (OR, 1.77; 95% CI, 1.04-3.03) ( Table 2 ). This risk increased as age at hypertension diagnosis decreased (P for trend, 0.02). Women who reported ever regular use of diuretics for hypertension or other reasons were at increased risk of breast cancer (OR, 1.79; 95% CI, 1.07-3.01). The associated risk of breast cancer increased with increasing duration of diuretic use (P for trend, o0.01).
Only 12 women (10 cases and two controls) reported use of reserpine, and there was no significant association with breast cancer risk (data not shown). Similarly, no significant associations between the group of 'other blood pressure medications' and breast cancer risk were apparent.
Stratified analyses revealed that the association between treated hypertension and breast cancer risk appeared to be stronger in the younger women (age 50-64 years), although the interaction term was not significant (w 2 for heterogeneity obtained from the logistic model ¼ 0.43; 1 df; P ¼ 0.51). After stratification by BMI, the association between treated hypertension and breast cancer risk remained significant (OR, 2.30; 95% CI, 1.12-4.71) for overweight women (BMI X25 kg/m 2 ) only and was no longer significant in normal weight women (w 2 for heterogeneity ¼ 2.7; 1 df; P ¼ 0.10) ( Table 3 ).
Discussion
The findings of the present study provide evidence in support of a positive modest association between treated hypertension and breast cancer risk among women aged 50-75 years. This risk appears to be stronger for those diagnosed with hypertension at a younger age (o50 years). In contrast, Soler et al. 9 reported similar ORs for breast cancer regardless of whether the diagnosis of hypertension occurred before or after age 55 years. However, Soler reported an OR of 1.34 for X5 years since hypertension diagnosis as compared to an OR of 1.12 for o5 years since hypertension diagnosis. Diuretic use, for treatment of hypertension or other reasons, was also found to be significantly associated with breast cancer risk in this study. Li et al. 20 conducted a detailed study on antihypertensive medications and found thiazide and potassiumsparing diuretics, but not loop diuretics, to be associated with a modest increase in breast cancer risk among post-menopausal women aged 65-79 years. In the present study, it cannot be ruled out, however, that the effect of diuretic use was owing to the underlying condition of hypertension, or vice versa.
Stratified analyses revealed that, consistent with previous studies, the breast cancer risk asso- ciated with treated hypertension also appears to be confined to women with a BMI of at least 25 kg/m 2 , a finding similar to that of Soler who reported a statistically significant OR associated with hypertension of 1.44 in women with a BMI of X25 kg/m 2 , and a non-significant OR of 1.06 among women with a BMI o25 kg/m 2 . When breast cancer risk associated with treated hypertension was examined by age strata, the present study reported a stronger risk among the younger women (age 50-64 years) as compared to those who were aged 65-75 years, although the groups were not found to be heterogeneous by statistical analysis. The observation that the age groups were statistically comparable coincides with that of Soler who reported similar ORs for women aged 55-64 and 65-74 years among a hospital-based sample of cases and controls.
Although there is no known explanation for the association between breast cancer and hypertension, several mechanisms have been proposed. Breast cancer and hypertension may share common pathophysiological pathways including those involved in inflammation and hormone synthesis and metabolism. Perhaps, an environment of chronic inflammation, induced by an abundance of adipose tissue, is driving both hypertension and breast cancer in these women. It has been hypothesized that chronic inflammation predisposes to cancer, 21 and also that vascular inflammation may be involved in the pathogenesis of hypertension. 22, 23 Another possible explanation is that steroid hormone factors are involved with the progression of both conditions. Estradiol exposure is implicated in the aetiology of breast cancer and has been hypothesized as having involvement in the development of hypertension, although perhaps serving a protective role. 24 Hypertension and BMI in our study population were found to be highly correlated (data not shown), yet BMI did not fully account for the association between treated hypertension and breast cancer risk in these analyses as BMI was included as a covariate. Similarly, a history of diabetes did not explain this association. It has also been hypothesized that the condition of hypertension itself may provide an environment which supports the development of cancer. Specifically, it has been theorized that long-term exposure (410 years) can lead to inhibition of apoptosis and thereby increase cancer risk. 25 The findings of an increased breast cancer risk associated with an earlier age at hypertension diagnosis in the present study are consistent with this theory.
A limitation of the present study is the reliance on self-report for both hypertension diagnosis and medication use and therefore a lack of information on blood pressure measurements. It is possible that cases may have had differential recall of events such as a hypertension diagnosis or that cases and controls may have been misclassified with respect to hypertension status or medication use. However, an effort was made to minimize this potential limitation by defining the main independent variable as 'treated hypertension' and combining the hypertension and medication use questions of the survey. Furthermore, information was lacking on specific subtypes of antihypertensive medications beyond diuretics and reserpine and therefore it is not possible to draw firm conclusions about other medications. Another limitation is that control subjects were enrolled approximately 4 years after cases. However, as prevalence of high BMI and hypertension are increasing over time, it is possible that the effects of both BMI and treated hypertension on breast cancer risk have been underestimated in this study. If the controls had been enrolled 4 years earlier they may have been even less likely to have high BMI and/or hypertension.
Strengths of the present study include the population-based ascertainment of both cases and controls, which lends support to the external validity of the findings, and the availability of information on both hypertension and medication use. The doseresponse effect observed between both the age at hypertension diagnosis and the duration of diuretic use and breast cancer risk decreases the likelihood that these were merely spurious associations.
Based on our results, we report a significant association between being diagnosed with breast cancer and a history of treated hypertension and diuretic drug use, with risk increasing for years of use. Further, we observed that this effect was strongest for overweight women. These results have implications for implementing cancer preventive strategies for those with hypertension, using diuretics and those that are overweight. Also, additional research into the pathways involved in the interrelationships between hypertension, antihypertensive medication use and breast cancer is warranted. What is known about this topic K Hypertension has been linked to some cancer types including renal and endometrial cancers [7] [8] [9] [10] [11] K Studies on hypertension and breast cancer have produced mixed results 4, 6, 9, [12] [13] [14] What this study adds K This study supports a positive association between treated hypertension and breast cancer among women aged 50-75 years after adjusting for age, BMI, diabetes, smoking, alcohol use, menopausal status, family history of breast or ovarian cancer, age at first full-term pregnancy and education K The association between hypertension and breast cancer was observed only among women with a BMI X25 kg/m 2 K A dose-response association was observed between duration of diuretic use and breast cancer risk Abbreviation: BMI, body mass index.
